These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 26277250

  • 21. Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease.
    Kosaraju J, Holsinger RMD, Guo L, Tam KY.
    Mol Neurobiol; 2017 Oct; 54(8):6074-6084. PubMed ID: 27699599
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions.
    Nishida S, Matsumura T, Senokuchi T, Murakami-Nishida S, Ishii N, Morita Y, Yagi Y, Motoshima H, Kondo T, Araki E.
    Biochem Biophys Res Commun; 2020 Mar 26; 524(1):8-15. PubMed ID: 31964532
    [Abstract] [Full Text] [Related]

  • 23. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Preserves Endothelial Function in Mesenteric Arteries from Type 1 Diabetic Rats without Decreasing Plasma Glucose.
    Salheen SM, Panchapakesan U, Pollock CA, Woodman OL.
    PLoS One; 2015 Mar 26; 10(11):e0143941. PubMed ID: 26618855
    [Abstract] [Full Text] [Related]

  • 24. Restoration of the endothelial function in the aortic rings of apolipoprotein E deficient mice by pharmacological inhibition of the nuclear enzyme poly(ADP-ribose) polymerase.
    Benkö R, Pacher P, Vaslin A, Kollai M, Szabó C.
    Life Sci; 2004 Jul 23; 75(10):1255-61. PubMed ID: 15219813
    [Abstract] [Full Text] [Related]

  • 25. A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4.
    Yamaguchi T, Watanabe A, Tanaka M, Shiota M, Osada-Oka M, Sano S, Yoshiyama M, Miura K, Kitajima S, Matsunaga S, Tomita S, Iwao H, Izumi Y.
    J Pharmacol Sci; 2019 Feb 23; 139(2):112-119. PubMed ID: 30638989
    [Abstract] [Full Text] [Related]

  • 26. Xyloketal B attenuates atherosclerotic plaque formation and endothelial dysfunction in apolipoprotein e deficient mice.
    Zhao LY, Li J, Yuan F, Li M, Zhang Q, Huang YY, Pang JY, Zhang B, Sun FY, Sun HS, Li Q, Cao L, Xie Y, Lin YC, Liu J, Tan HM, Wang GL.
    Mar Drugs; 2015 Apr 14; 13(4):2306-26. PubMed ID: 25874925
    [Abstract] [Full Text] [Related]

  • 27. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.
    Terawaki Y, Nomiyama T, Kawanami T, Hamaguchi Y, Takahashi H, Tanaka T, Murase K, Nagaishi R, Tanabe M, Yanase T.
    Cardiovasc Diabetol; 2014 Nov 19; 13():154. PubMed ID: 25407968
    [Abstract] [Full Text] [Related]

  • 28. A Dipeptidyl Peptidase-4 Inhibitor but not Incretins Suppresses Abdominal Aortic Aneurysms in Angiotensin II-Infused Apolipoprotein E-Null Mice.
    Kohashi K, Hiromura M, Mori Y, Terasaki M, Watanabe T, Kushima H, Shinmura K, Tomoyasu M, Nagashima M, Hirano T.
    J Atheroscler Thromb; 2016 Nov 19; 23(4):441-54. PubMed ID: 26549734
    [Abstract] [Full Text] [Related]

  • 29. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans.
    Batchu SN, Yerra VG, Liu Y, Advani SL, Klein T, Advani A.
    Int J Mol Sci; 2020 Aug 11; 21(16):. PubMed ID: 32796688
    [Abstract] [Full Text] [Related]

  • 30. Mechanisms of GLP-1 receptor-independent renoprotective effects of the dipeptidyl peptidase type 4 inhibitor linagliptin in GLP-1 receptor knockout mice with 5/6 nephrectomy.
    Hasan AA, von Websky K, Reichetzeder C, Tsuprykov O, Gaballa MMS, Guo J, Zeng S, Delić D, Tammen H, Klein T, Kleuser B, Hocher B.
    Kidney Int; 2019 Jun 11; 95(6):1373-1388. PubMed ID: 30979564
    [Abstract] [Full Text] [Related]

  • 31. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice.
    Nakaoku Y, Saito S, Yamamoto Y, Maki T, Takahashi R, Ihara M.
    Int J Mol Sci; 2019 May 23; 20(10):. PubMed ID: 31126115
    [Abstract] [Full Text] [Related]

  • 32. Effects of dipeptidyl peptidase 4 inhibition on inflammation in atherosclerosis: A 18F-fluorodeoxyglucose study of a mouse model of atherosclerosis and type 2 diabetes.
    Virta J, Hellberg S, Liljenbäck H, Ståhle M, Silvola JMU, Huusko J, Söderström M, Knuuti J, Nuutila P, Ylä-Herttuala S, Gomez MF, Roivainen A, Saraste A.
    Atherosclerosis; 2020 Jul 23; 305():64-72. PubMed ID: 32386751
    [Abstract] [Full Text] [Related]

  • 33. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.
    Gaspari T, Liu H, Welungoda I, Hu Y, Widdop RE, Knudsen LB, Simpson RW, Dear AE.
    Diab Vasc Dis Res; 2011 Apr 23; 8(2):117-24. PubMed ID: 21562063
    [Abstract] [Full Text] [Related]

  • 34. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice.
    Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, Laufs U.
    Circulation; 2008 May 06; 117(18):2377-87. PubMed ID: 18443241
    [Abstract] [Full Text] [Related]

  • 35. Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia.
    Steven S, Hausding M, Kröller-Schön S, Mader M, Mikhed Y, Stamm P, Zinßius E, Pfeffer A, Welschof P, Agdauletova S, Sudowe S, Li H, Oelze M, Schulz E, Klein T, Münzel T, Daiber A.
    Basic Res Cardiol; 2015 Mar 06; 110(2):6. PubMed ID: 25600227
    [Abstract] [Full Text] [Related]

  • 36. The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation.
    Ide M, Sonoda N, Inoue T, Kimura S, Minami Y, Makimura H, Hayashida E, Hyodo F, Yamato M, Takayanagi R, Inoguchi T.
    PLoS One; 2020 Mar 06; 15(2):e0228750. PubMed ID: 32032367
    [Abstract] [Full Text] [Related]

  • 37. Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice.
    Kanda J, Furukawa M, Izumo N, Shimakura T, Yamamoto N, Takahashi HE, Wakabayashi H.
    Drug Discov Ther; 2020 Nov 04; 14(5):218-225. PubMed ID: 33116039
    [Abstract] [Full Text] [Related]

  • 38. Endothelial function in aorta segments of apolipoprotein E-deficient mice before development of atherosclerotic lesions.
    Fransen P, Van Assche T, Guns PJ, Van Hove CE, De Keulenaer GW, Herman AG, Bult H.
    Pflugers Arch; 2008 Feb 04; 455(5):811-8. PubMed ID: 17899169
    [Abstract] [Full Text] [Related]

  • 39. Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice.
    Baumhäkel M, Custodis F, Schlimmer N, Laufs U, Böhm M.
    Atherosclerosis; 2010 Sep 04; 212(1):55-62. PubMed ID: 20347444
    [Abstract] [Full Text] [Related]

  • 40. Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells.
    Lee MY, Li H, Xiao Y, Zhou Z, Xu A, Vanhoutte PM.
    Br J Pharmacol; 2011 Apr 04; 162(7):1564-76. PubMed ID: 21175571
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.